Life sciences firmHikal Ltd on Friday announced the successful development of Favipiravir active pharmaceutical ingredient (API) and its intermediates.
Antiviral drug Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co Ltd, Japan, a subsidiary of Fujifilm Corporation, Hikal said in a BSE filing.
The drug has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections, it added.
Favipiraviris in various stages of clinical trials in many countries as an experimental treatment of COVID-19, Hikal said.
"The company is in discussion with potential partners to supply the API and its intermediates," it added.
Shares of Hikal Ltd were trading at Rs114.95apiece on the BSE, up 4.98 per cent over previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app